Resistance training raises muscle NAD+ by 127%, whereas oral precursor supplements have failed to alter muscle NAD+ across three separate randomised human biopsy trials. Every guide we write starts from what was measured, and here that means asking which tissue.
Current human data shows exercise stimulates muscle NAD+ synthesis directly. Precursor supplements only show clear increases in blood cells. The biopsy trials and the blood trials report different results.
The Verdict
What Training Does to Muscle NAD+ and What Supplements Do Not
Ten weeks of supervised resistance training raised skeletal muscle NAD+ by 127% in middle-aged adults.
A resistance-training study examined 16 overweight, previously untrained men and women with an average age of 59. The resistance programme doubled muscle tissue NAD+ and increased muscle NADH by 99%.
Nicotinamide phosphoribosyltransferase (NAMPT) protein abundance rose 15% alongside a 13% increase in global sirtuin activity. Functional strength also improved. Participants increased knee-extensor peak torque and vastus lateralis muscle thickness over the 10 weeks.
This trial had one major limitation: it lacked an untrained control group. Researchers compared post-training tissue values against an independent cohort of active college-aged men. The workout programme restored older muscle metabolites to young adult benchmarks.
Endurance training produces similar enzymatic adaptations in human skeletal muscle. Just three weeks of supervised cycling increased muscle NAMPT abundance by 127% in sedentary adults. Muscle NAMPT levels correlate directly with aerobic fitness as measured by VO2 max.
| Exercise Modality | Trial Cohort | Protocol Duration | Measured Muscle Outcome |
|---|---|---|---|
| Resistance training | 16 untrained adults, mean age 59 | 10 weeks, twice weekly | 127% increase in muscle NAD+, 15% increase in NAMPT, improved knee torque |
| Endurance cycling | 13 sedentary adults | 3 weeks, 13 supervised sessions | 127% increase in NAMPT protein, no change in controls |
| Mixed age training | 21 young and 22 older adults per mode; age correlation across 57 people aged 18 to 84 | 12 weeks, aerobic or resistance | Resistance raised NAMPT 25% in young and 30% in older; aerobic raised NAMPT 12% and 28% |
Biological Roles of NAD and Exercise in Skeletal Muscle
Contracting skeletal muscle requires nicotinamide adenine dinucleotide (NAD+) as an essential electron carrier during glycolysis and the tricarboxylic acid cycle.
During continuous muscle work, NAD+ accepts hydride ions to become NADH at glyceraldehyde-3-phosphate dehydrogenase. Mitochondrial complex I then oxidises NADH back into NAD+ to sustain adenosine triphosphate (ATP) production.
Metabolic enzymes cycle this cellular pool continuously without destroying the underlying molecules. Other cellular systems consume NAD+ completely. Sirtuins and poly(ADP-ribose) polymerases (PARPs) cleave NAD+ during cellular signaling and DNA repair.
Because signaling enzymes destroy NAD+, muscle cells must constantly rebuild their supply through the salvage pathway. NAMPT catalyses the rate-limiting step by converting nicotinamide back into precursor intermediates.
Higher NAD+ availability activates sirtuin 1 (SIRT1), stimulating mitochondrial biogenesis through PGC-1-alpha. Our guide on what NAD+ does explains these cellular salvage pathways in full detail.
The Compartment Split Between Blood and Skeletal Muscle
Oral precursor supplements reliably elevate NAD+ in circulating blood cells while leaving skeletal muscle concentrations unchanged.
This anatomical distinction represents the central disconnect in precursor marketing. Commercial advertisements cite clinical trials showing blood levels doubling after oral supplementation.
In healthy volunteers, daily doses of nicotinamide riboside (NR) raised whole-blood NAD+ by up to 142%. Similar trials in clinical populations reported blood increases of two- to fivefold. Circulating white blood cells absorb and metabolise these oral compounds rapidly.
Three biopsy trials report the opposite result. In 12 older men taking 1,000 mg of NR daily for 21 days, muscle tissue NAD+ remained unchanged. Biopsies showed 210 pmol/mg in the supplement group versus 197 pmol/mg in the placebo group.
Nicotinic acid adenine dinucleotide (NAAD) and clearance metabolites rose, proving absorption occurred, yet functional parameters did not budge. Mitochondrial respiration, citrate synthase activity, and handgrip strength were identical between groups. Our review of grip strength by age covers functional force metrics in detail.
| Trial Cohort | Dose and Duration | Blood Finding | Muscle Biopsy Finding |
|---|---|---|---|
| 12 older men, median age 75 | 1,000 mg daily for 21 days | Systemic clearance products rose 5- to 6-fold | Muscle NAD+ unchanged (210 vs 197 pmol/mg, P = 0.22); respiration and grip unchanged |
| 8 healthy young men | 1,000 mg daily for 7 days | Systemic absorption confirmed | Muscle NAD+ unchanged; no change in exercise signalling pathways |
| 40 obese insulin-resistant men | 1,000 mg twice daily for 12 weeks | Systemic metabolites increased | Muscle NAD+ metabolites unchanged; mitochondrial capacity unchanged; muscle NAMPT decreased |
Precursor Trials on NAD and Exercise in Healthy Adults
No randomised controlled trial has demonstrated that precursor supplementation improves athletic performance in trained young athletes.
Sports scientists have looked specifically for performance advantages in healthy populations. An exhaustive 2022 sports physiology review evaluated NAD-targeted therapeutics across exercise adaptations in humans.
The authors concluded that precursor compounds do not alter skeletal muscle metabolism or enhance training adaptation in healthy individuals. In a dedicated trial of eight healthy young men, seven days of 1,000 mg daily NR failed to alter metabolic signaling. The supplement did not modify the molecular cascades regulating mitochondrial adaptation after acute endurance exercise.
Combining precursors with physical training produces no measurable synergy. A trial of 54 older adults combined 1,000 mg daily NR with six weeks of supervised walking. Blood pressure and aerobic adaptations were statistically identical between the supplement and placebo groups.
Precursors added to a walking regimen did not generate superior cardiovascular results. Readers training for endurance should consult our guide on zone 2 cardio training for proven aerobic conditioning methods.
Commercial Sponsorship and Data Gaps in NMN Trials
Every published human trial reporting an exercise performance benefit from NMN has relied on commercial supplement industry funding.
The most widely cited trial examined 48 amateur runners randomly assigned to placebo, 300, 600, or 1,200 mg of NMN daily. Researchers reported greater improvements in ventilatory threshold power in the medium- and high-dose groups compared to controls.
The trial found no significant difference in maximal oxygen consumption, peak power output, or heart rate recovery. The researchers never measured blood or muscle NAD+ at any point. The proposed physiological mechanism was never verified in the study cohort.
A commercial manufacturer provided all the active and placebo capsules. A separate 60-day trial in 80 middle-aged adults reported substantial increases in six-minute walking distance. That study had noticeable baseline performance disparities between randomised cohorts.
The paper was funded directly by two supplement firms, with corporate employees listed among the co-authors. A 2025 meta-analysis of ten randomised trials found no significant effect of NMN or NR on gait speed, grip strength, or muscle mass. For details on studied intake levels, see our breakdown of NMN dosage research.
Walking Capacity in Clinical and Deconditioned Cohorts
Physical functional gains from NAD+ precursors appear almost exclusively in clinical populations with existing circulatory or metabolic disease.
A six-month randomised trial evaluated 1,000 mg daily NR in 90 patients with lower-extremity peripheral artery disease. Participants suffered from severe claudication that restricted their walking ability.
The NR group increased six-minute walk distance by 17.6 metres relative to placebo. However, the researchers reported this primary endpoint with an unconventional one-sided 90% confidence interval and a P-value of 0.08. Objective daily physical activity and subjective impairment questionnaires showed no difference between treatments.
In the muscle biopsy sub-study of that trial, tissue NAD+ did not differ between the supplement and placebo groups. Combining NR with resveratrol produced no walking distance benefit while causing gastrointestinal distress in over half of recipients.
In metabolic trials of obese adults, 1,000 mg daily NR increased fat-free mass by 1.34% over six weeks. Hyperinsulinaemic clamp testing confirmed that muscle insulin sensitivity remained unchanged. Healthy athletes cannot extrapolate walking tolerance gains seen in claudication patients to athletic conditioning.
Age-Related Muscle Decline and the Mouse Causality Challenge
Observational human studies show reduced muscle NAD+ in older adults, but physical inactivity confounds whether chronological aging causes the decline.
Cross-sectional tissue analyses consistently find lower NAD+ concentrations in sarcopenic and physically impaired older individuals. Muscle biopsies from 119 older men in Singapore, Hertfordshire, and Jamaica revealed disrupted NAD+ salvage pathways in sarcopenic subjects.
Yet the same human datasets show that exercise-trained older adults possess muscle NAD+ levels comparable to young adults. Tissue NAD+ abundance tracks average daily step counts and general physical function. Physical sedentary time might drive the decline rather than an inevitable biological clock.
To understand structural muscle loss with age, read our analysis on whether sarcopenia is reversible. A 2025 genetic investigation in mice challenged the assumption that NAD+ depletion causes muscle deterioration. Scientists disrupted muscle-specific NAMPT, depleting skeletal muscle NAD+ by 85% in mice.
The mice maintained normal muscle contractility, exercise capacity, mitochondrial structure, and proteomic integrity. Lifelong tissue NAD+ depletion in these mice did not accelerate muscle aging. Human correlational studies must not be confused with interventional causation.
Regulatory Clarification and Product Safety Evidence
In December 2025, the Food and Drug Administration (FDA) formally determined that NMN is not excluded from the dietary supplement definition.
The decision reversed an administrative exclusion put in place in late 2022. The agency had previously restricted NMN sales after authorizing clinical drug investigations.
That regulatory reversal addressed only statutory marketing classification. It does not constitute government validation of safety, efficacy, or athletic claims. Nicotinamide riboside chloride maintains an older regulatory standing under FDA GRAS Notice GRN 635 from 2016.
You can review the regulatory history in our comparison of NMN and NR. Human safety profiles in short-term trials appear relatively benign. In healthy volunteers taking 1,000 mg of NR daily for eight weeks, adverse events did not differ from placebo.
Trials in Parkinson's disease noted a slight initial rise in serum homocysteine at higher doses. Check our summary of NMN side effects for trial tolerability data.
Practical Verdict on NAD and Exercise Interventions
Skeletal muscle tissue adaptations respond to progressive physical training rather than precursor supplement regimens.
The evidence shows that ten weeks of lifting weights doubles muscle NAD+ in middle-aged humans. Three independent biopsy trials showed oral NR supplements left muscle NAD+ unchanged.
This assessment does not apply to clinical patients managing peripheral artery disease or metabolic failure. Those patient groups operate under distinct pathological constraints and might derive specific functional benefits.
What would change this perspective is an independently funded human trial in trained athletes demonstrating that a precursor elevates muscle tissue NAD+ while boosting performance. Every component of that evidentiary chain is missing today.
Athletes seeking validated interventions should examine our analysis of creatine for longevity to evaluate supplements with direct tissue evidence. On the published record, structured resistance and aerobic training is the intervention with muscle-tissue evidence behind it, and oral NAD and exercise supplements are not.
Frequently Asked Questions
Does exercise raise NAD+ levels?
Exercise raises NAD+ and its rate-limiting enzyme in human skeletal muscle. A 10-week resistance training trial in middle-aged adults demonstrated a 127% increase in muscle tissue NAD+ alongside a 15% increase in NAMPT protein abundance and a 13% increase in global sirtuin activity. Three weeks of endurance cycling also increased muscle NAMPT abundance by 127% in sedentary adults. Cross-sectional data confirm that trained endurance athletes possess roughly twofold higher baseline muscle NAMPT levels than sedentary controls. Unlike oral supplements, physical exercise stimulates the enzymatic salvage pathway directly inside contracting muscle fibres.
Do NAD+ supplements improve athletic performance?
Published human trials do not show that NAD+ supplements improve performance in trained athletes. A 2022 review in sports physiology evaluated the available literature and concluded that precursor supplementation fails to improve training adaptations or exercise performance in healthy individuals. The widely cited amateur runner study tested 300 to 1,200 mg daily of NMN across six weeks and found no change in VO2max, peak power output, or heart rate recovery. Furthermore, a 2025 meta-analysis pooling ten randomised controlled trials found no significant improvement in gait speed, chair-stand time, or handgrip strength. Functional gains have appeared only in deconditioned clinical populations.
Does NR actually raise NAD+ in muscle?
Three separate randomised, placebo-controlled muscle biopsy trials found that oral nicotinamide riboside did not raise NAD+ concentrations in human skeletal muscle. In 12 older men receiving 1,000 mg daily for 21 days, muscle NAD+ remained identical between NR and placebo groups at 210 versus 197 pmol/mg. A seven-day study of 1,000 mg daily in eight healthy young men similarly showed no change in muscle tissue NAD+ or exercise-induced mitochondrial signaling. Finally, a 12-week trial in 40 insulin-resistant men found no change in muscle NAD+ metabolites and observed a decrease in muscle NAMPT protein abundance. NR changes blood markers, but not muscle tissue.
Is NMN legal to sell as a supplement?
NMN is legal to market as a dietary supplement in the United States following a Food and Drug Administration decision issued on 2 December 2025. The agency formally reconsidered its statutory interpretation and set aside its late-2022 letters that had excluded NMN from the supplement definition due to prior investigational drug filings. This administrative reversal restored NMN to dietary ingredient status under federal law. However, the ruling addresses only commercial classification. It does not certify that NMN is safe, effective, or capable of improving athletic capacity. Individual suppliers must still comply with standard dietary ingredient notification and manufacturing regulations.
Does NAD+ really decline with age?
Muscle NAD+ is lower in sedentary older adults, but physical inactivity explains much of the observed difference. Biopsies from older men show lower NAD+ concentrations in sarcopenic individuals compared to healthy peers. However, older adults who maintain regular exercise habits exhibit muscle NAD+ levels indistinguishable from active young adults. In addition, a 2025 study in mice demonstrated that an 85% genetic depletion of muscle NAD+ failed to alter muscle contractility, mitochondrial structure, or running endurance, and did not accelerate aging. Human decline appears closely tied to muscle disuse rather than an unavoidable biological timer.
Should athletes take NMN or NR?
Current scientific evidence does not justify competitive or recreational athletes purchasing NMN or NR for performance gains. No randomised controlled trial has shown improved work capacity, recovery, or VO2max in healthy trained individuals. Oral precursors elevate circulating blood markers without altering skeletal muscle NAD+ pools or mitochondrial adaptations to training bouts. The few positive exercise signals in the literature come from trials funded by commercial supplement producers and lack tissue-level verification. The measured enzymatic and metabolic adaptations in these trials came from progressive resistance training and structured aerobic work, not from precursor capsules.
Why do blood NAD+ results look so much better than muscle results?
Circulating blood cells and skeletal muscle tissue handle oral precursors through completely different metabolic pathways. Oral NR and NMN enter the bloodstream and undergo rapid uptake by red blood cells, white blood cells, and platelets, which lack tight intracellular feedback restrictions. This cellular uptake causes whole-blood NAD+ measurements to surge by 100% or more in clinical assays. Skeletal muscle fibres, in contrast, maintain autonomous homeostatic controls and rely primarily on intracellular salvage via the NAMPT enzyme rather than absorbing intact circulating precursors. Commercial marketing promotes the dramatic blood figures while ignoring the unchanged tissue biopsies.